IMS 2025: Key Sessions & Presentations | Pharmacy Times

Key Takeaways from the Multiple Myeloma Conference (IMS 2025)

This text summarizes discussions from experts at a multiple ‍myeloma conference (IMS 2025). Here’s⁣ a breakdown of the key themes and emerging trends:

1. Shorter Treatment Durations & potential for “Curative” Approaches:

* A major goal is to reduce treatment duration. The hope is to move towards regimens similar to lymphoma, were treatment can be completed in 6 months (e.g., bispecifics + combo drugs).
* There’s growing evidence that myeloma doesn’t always require continuous maintenance therapy.
* Real-world data ⁣shows long-term remission even after stopping bispecific treatment,supporting the idea of limited-duration therapy.

2. Advancements in Immunotherapy:

* Bispecific Antibodies: Continued research on bispecifics (including cevostamab) and their long-term effects. focus on understanding when they work best and how long treatment needs to be. Combinations with drugs like carfilzomib are being explored.
* CAR T-cell Therapy: New⁢ CAR T constructs are being developed, with a focus on managing and mitigating toxicities. ⁢ Bispecifics are being considered after CAR T therapy.
* Trispecific Antibodies: Emerging data on ⁤trispecific antibodies.
* Allogeneic CAR T: research into allogeneic (off-the-shelf) CAR T therapies.

3.Understanding resistance & Personalizing Treatment:

* A key ambition is to identify mechanisms of resistance to therapies.
* ⁢ Circulating⁢ plasma ‍cells are being recognized as important factors to study in patients.
* Molecular evaluation is crucial for understanding treatment response and resistance.
* The goal is to personalize treatment based on individual patient profiles and resistance signatures.

4. Real-World Evidence & Toxicity Management:

* real-world data is vital for understanding treatment outcomes and uncommon severe toxicities.
* Focus on identifying patients at risk for toxicities and developing mitigation strategies.

5. Quadruplet Regimens as Potential New Standard of Care:

* Quadruplet regimens are being investigated as a potential new standard of care for frontline multiple myeloma.

Overall ⁢Impression:

The experts are optimistic about the rapid evolution of myeloma treatment. While many of the combinations presented aren’t yet practice-changing, they represent important progress towards more effective, shorter, and ‍personalized therapies. The conference highlighted a shift towards possibly achieving deeper, more durable remissions and even, ultimately, a more “curative” approach to the disease.